Taxanes as radiosensitizers for head and neck cancer

Current Opinion in Oncology

Volumn 11, Issue 3, 1999, Pages 183-186

  Herscher, Laurie L ^a   Cook, John ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; HYDROXYUREA; PACLITAXEL; RADIOSENSITIZING AGENT; TAXANE DERIVATIVE;

CANCER STAGING; CLINICAL TRIAL; FEVER; HEAD AND NECK CANCER; HUMAN; META ANALYSIS; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CISPLATIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; PACLITAXEL; RADIATION-SENSITIZING AGENTS;

EID: 0032945705     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199905000-00008     Document Type: Review

References (22)

1. Ojima I, Kuduk SD, Pera P, Veith JM, Bernacki RJ: Synthesis and structure-activity relationships of nonaromatic taxoids: effects of alkyl and alkenyl ester groups on cytotoxicity. J Med Chem 1997, 40:279-285.
2. Ojima I, Slater JC, Kuduk SD, Takeuchi CS, Gimi RH, Sun CM, et al.: Synthesis and structure-activity relationships of taxoids derived from 14 beta-hydroxy-10-deacetylabaccatin III. J Med Chem 1997, 31:267-278.
3. Scatena CD, Stewart ZA, Mays D, Tang LJ, Keffer CJ, Leach SD, Pietenpol JA: Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 1998, 273:30777-30784. Interesting paper detailing the relationship between taxol and apoptosis showing that phosphorylation of Bcl-2 is modified by taxol.
4. Ling YH, Tornos C, Perez-Soler R: Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem 1998, 273:18984-18991. Interesting paper that demonstrates that the phosphorylation of Bcl-2 may not be the primary effect of taxol but rather a secondary effect due to the G2/M block by taxol.
5. Torres K, Horwitz SB: Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998, 58:3620-3626.
6. Moos PJ, Fitzpatrick FA: Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits. Cell Growth Diff 1998, 9:687-697
7. Kearns CM: Pharmacokinetics of the Taxanes. Pharmacotherapy 1997, 17(suppl): 105-109.
8. Dorr RT: Pharmacology of the Taxanes. Pharmacotherapy 1997, 17(suppl):96-104.
9. Leibmann J, Cook J, Lipschultz C, Teague D, Fisher J, Mitchell JB: The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human cell lines. Cancer Chemother Pharmacol 1994, 33:331-339.
10. Endicott JA, Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 1989, 58:137-171.
11. Van Ark-Otte J, Samelis G, Rubio G, Saez JBL, Pinedo HM, Giaccone G: Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 1998, 5:249-255.
12. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al.: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258:1650-1654.
13. Kowalski R, Giannakakou P, Gunasekera S, Longley R, Day B, Hamel E: The microtubule-stabilizing agent Discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997, 52:613-622.
14. Terasima T, Tolmach LJ: Changes in x-ray sensitivity of HeLa cells during the division cycle. Nature 1961, 190:1210-1211.
15. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ: Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 1995, 55:3564-3568.
16. Hoffmann W, Belka C, Schmidberger H, Budach w, Bochtler H, Hess C, Bamberg M: Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer: results from a phase I trial. Int J Radiol Oncol Biol Phys 1997, 38:691-696.
17. Steinberg L, Hassan M, Olmsted L, Sharan V, Stepnick D, Hoppel C, et al.: A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma. Semin Oncol 1997, 24:51-56.
18. Rosenthal D, Sinard R, Okani O, Corak J, Kavanaugh D, Kamen B, et al.: Seven-week continous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: a phase I study. Semin Oncol 1997, 24:67-71. This paper presents an interesting and novel approach to the use of taxol as a radiosensitizer with a good discussion of radiobiologic princples underlying this approach and an attempt at clinical correlation with preclinical data.
19. Brockstein B, Haraf D, Stenson K, Fasanmade A, Stupp R, Glisson B, et al.: Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 1998, 16:735-744.
20. Vokes EE, Panje WR, Schilsky RL, Mick R, Awan AM, Moran WJ, et al.: Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol 1989, 7:761-768.
21. Chougule P, Wanebo H, Akerley W, McRae R, Nigri P, Leone L, et al.: Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study - preliminary results. Semin Oncol 24:57-61.
22. Wanebo H, Chougule P, Akerley W, Koness RJ, McRae R, Nigri P, et al.: Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer. Am J Surg 1997, 174:518-522.